Ömer Güneş, Saliha Kanık-Yüksek, Aylin Kayalı-Akyol, Özhan Akyol, Ahmet Yasin Güney, Fatih Üçkardeş, Aysun Yahşi, Seval Özen, Tuğba Erat, Belgin Gülhan, Gülsüm İclal Bayhan, Aslınur Özkaya-Parlakay
{"title":"抗生素治疗儿科金黄色葡萄球菌菌血症的临床效果比较。","authors":"Ömer Güneş, Saliha Kanık-Yüksek, Aylin Kayalı-Akyol, Özhan Akyol, Ahmet Yasin Güney, Fatih Üçkardeş, Aysun Yahşi, Seval Özen, Tuğba Erat, Belgin Gülhan, Gülsüm İclal Bayhan, Aslınur Özkaya-Parlakay","doi":"10.1080/14787210.2025.2493075","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the risk factors, clinical features, and clinical outcomes among pediatric hospitalized patients receiving treatment for <i>Staphylococcus aureus</i> bacteremia and compare the effects of antibiotics used in the treatment on clinical outcomes.</p><p><strong>Research design and methods: </strong>This single-center retrospective study included patients aged between 1 month and 18 years who received treatment for Staphylococcus aureus bacteremia (SAB) betweenSeptember 2019 and September 2022.</p><p><strong>Results: </strong>SAB was detected in 95 pediatric patients. In MRSA bacteremias, no difference in clinical outcomes was found between patients receiving vancomycin or teicoplanin. In MSSA bacteremias, the recurrence rate of SAB was 0% in the penicillin group and 23.5% in the cephalosporin group. The median duration of bacteremia-related hospital stay (10 vs. 14 days), and the median duration of bacteremia (2 vs. 3 days) were shorter in the ampicillin-sulbactam group than in the piperacillin-tazobactam group (<i>p</i> = 0.016, and <i>p</i> = 0.050, respectively).</p><p><strong>Conclusions: </strong>Teicoplanin was found to have similar clinical outcomes to vancomycin in treating MRSA bacteremia. In addition, ampicillin sulbactam was found to have better clinical outcomes than other antibiotics in treating MSSA bacteremia. Teicoplanin and ampicillin sulbactam may be considered as a choice in the treatment of pediatric SAB.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":4.2000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of clinical outcomes of antibiotics used for <i>Staphylococcus aureus</i> bacteremia in pediatric patients.\",\"authors\":\"Ömer Güneş, Saliha Kanık-Yüksek, Aylin Kayalı-Akyol, Özhan Akyol, Ahmet Yasin Güney, Fatih Üçkardeş, Aysun Yahşi, Seval Özen, Tuğba Erat, Belgin Gülhan, Gülsüm İclal Bayhan, Aslınur Özkaya-Parlakay\",\"doi\":\"10.1080/14787210.2025.2493075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aims to evaluate the risk factors, clinical features, and clinical outcomes among pediatric hospitalized patients receiving treatment for <i>Staphylococcus aureus</i> bacteremia and compare the effects of antibiotics used in the treatment on clinical outcomes.</p><p><strong>Research design and methods: </strong>This single-center retrospective study included patients aged between 1 month and 18 years who received treatment for Staphylococcus aureus bacteremia (SAB) betweenSeptember 2019 and September 2022.</p><p><strong>Results: </strong>SAB was detected in 95 pediatric patients. In MRSA bacteremias, no difference in clinical outcomes was found between patients receiving vancomycin or teicoplanin. In MSSA bacteremias, the recurrence rate of SAB was 0% in the penicillin group and 23.5% in the cephalosporin group. The median duration of bacteremia-related hospital stay (10 vs. 14 days), and the median duration of bacteremia (2 vs. 3 days) were shorter in the ampicillin-sulbactam group than in the piperacillin-tazobactam group (<i>p</i> = 0.016, and <i>p</i> = 0.050, respectively).</p><p><strong>Conclusions: </strong>Teicoplanin was found to have similar clinical outcomes to vancomycin in treating MRSA bacteremia. In addition, ampicillin sulbactam was found to have better clinical outcomes than other antibiotics in treating MSSA bacteremia. Teicoplanin and ampicillin sulbactam may be considered as a choice in the treatment of pediatric SAB.</p>\",\"PeriodicalId\":12213,\"journal\":{\"name\":\"Expert Review of Anti-infective Therapy\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anti-infective Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14787210.2025.2493075\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2025.2493075","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景：本研究旨在评价接受金黄色葡萄球菌菌血症治疗的儿科住院患者的危险因素、临床特点和临床转归，并比较治疗中使用的抗生素对临床转归的影响。研究设计和方法：本单中心回顾性研究纳入2019年9月至2022年9月期间接受金黄色葡萄球菌菌血症（SAB）治疗的年龄在1个月至18岁之间的患者。结果：95例患儿检出SAB。在MRSA菌血症中，接受万古霉素或替可普宁治疗的患者的临床结果没有差异。MSSA菌血症中，青霉素组SAB复发率为0%，头孢菌素组SAB复发率为23.5%。氨苄西林-舒巴坦组中位菌血症相关住院时间（10天vs 14天）和中位菌血症持续时间（2天vs 3天）均短于哌拉西林-他唑巴坦组（p = 0.016, p = 0.050）。结论：替柯planin治疗MRSA菌血症的临床结果与万古霉素相似。此外，氨苄西林舒巴坦治疗MSSA菌血症的临床效果优于其他抗生素。替柯planin和氨苄西林舒巴坦可作为儿童SAB治疗的选择。
Comparison of clinical outcomes of antibiotics used for Staphylococcus aureus bacteremia in pediatric patients.
Background: This study aims to evaluate the risk factors, clinical features, and clinical outcomes among pediatric hospitalized patients receiving treatment for Staphylococcus aureus bacteremia and compare the effects of antibiotics used in the treatment on clinical outcomes.
Research design and methods: This single-center retrospective study included patients aged between 1 month and 18 years who received treatment for Staphylococcus aureus bacteremia (SAB) betweenSeptember 2019 and September 2022.
Results: SAB was detected in 95 pediatric patients. In MRSA bacteremias, no difference in clinical outcomes was found between patients receiving vancomycin or teicoplanin. In MSSA bacteremias, the recurrence rate of SAB was 0% in the penicillin group and 23.5% in the cephalosporin group. The median duration of bacteremia-related hospital stay (10 vs. 14 days), and the median duration of bacteremia (2 vs. 3 days) were shorter in the ampicillin-sulbactam group than in the piperacillin-tazobactam group (p = 0.016, and p = 0.050, respectively).
Conclusions: Teicoplanin was found to have similar clinical outcomes to vancomycin in treating MRSA bacteremia. In addition, ampicillin sulbactam was found to have better clinical outcomes than other antibiotics in treating MSSA bacteremia. Teicoplanin and ampicillin sulbactam may be considered as a choice in the treatment of pediatric SAB.
期刊介绍：
Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
